
ICON Public Limited Company
ICLRNASDAQHealthcareMedical - Diagnostics & Research
Previous close
$172.23
−$2.035 · -1.17%
ICLR company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
79
Undervalued
Momentum
51
Neutral
Sentiment
54
Mixed
Risk resilience
50
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- Headquarters
- IE
- CEO
- Barry Balfe
- Listed since
- May 15, 1998
- Employees
- 40,200
Market position
Day range
Current $172.23
52-week range
Current $172.23
- Open
- $176.11
- Previous close
- $174.27
- Volume
- 391.18K
- 0.37× average
- Average volume
- 1.06M
- Average daily volume
- Market cap
- 13.19B USD
- Beta
- 1.2
- Market reference 1
- 50-day average
- $164.27
- +4.85% above average
- 200-day average
- $147.14
- +17.05% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 17.2B USD
- EV / EBITDA
- 20.88×
- Earnings yield
- 1.60%
- Free cash flow yield
- 6.03%
Profitability & efficiency
- Return on equity
- 2.49%
- Return on assets
- 1.41%
- Return on invested capital
- 6.74%
Financial health
- Current ratio
- 1.1×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 8.25B USD | 8.28B USD | 8.12B USD | 7.74B USD | 5.48B USD |
| Cost of goods sold | 6.08B USD | 5.85B USD | 5.72B USD | 5.53B USD | 3.97B USD |
| Gross profit | 2.18B USD | 2.44B USD | 2.4B USD | 2.21B USD | 1.51B USD |
| Selling, general, and administrative | 780.14M USD | 728.35M USD | 776.36M USD | 778.75M USD | 585.33M USD |
| Operating expenses | 1.16B USD | 1.34B USD | 1.44B USD | 1.42B USD | 1.13B USD |
| Interest income | 7.11M USD | 8.61M USD | 5.01M USD | 2.35M USD | 574K USD |
| Interest expense | 188.11M USD | 237.24M USD | 336.7M USD | 229.73M USD | 182.42M USD |
| Depreciation and amortization | 383M USD | 488.5M USD | 585.95M USD | 614.73M USD | 360.33M USD |
| Operating income | 1.01B USD | 1.1B USD | 956.15M USD | 795.24M USD | 378.53M USD |
| Net income | 229.34M USD | 791.47M USD | 612.34M USD | 505.3M USD | 153.19M USD |
Company facts updated Aug 24, 2026.
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$170.64
0.92% downsideRecent analyst actions
ICLR peers
ETFs holding ICLR
Funds reporting this stock among their holdings, ordered by reported position size.
Dimensional - US Small Cap Value ETFDFSV37.35M0.45%8.42B USD0.30%$40.29+0.72%
Dimensional - US Targeted Value ETFDFAT19.82M0.14%14.66B USD0.28%$71.67+0.67%
State Street SPDR Portfolio Developed World ex-US ETFSPDW16.86M0.04%41.92B USD0.03%$52.02+0.79%
Thrivent Small-Mid Cap Equity ETFTSME16.13M1.66%968.94M USD0.65%$48.61+0.81%
Dimensional - US Core Equity 2 ETFDFAC14.31M0.03%49.31B USD0.17%$45.61+0.46%
Distillate U.S. Fundamental Stability & Value ETFDSTL14.05M0.67%1.95B USD0.39%$69.81+0.95%
Brown Advisory Sustainable Value ETFBASV11.11M2.62%216.19M USD0.71%$31.9487+0.44%
Vanguard Total World Stock ETFVT10.25M0.01%97.9B USD0.06%$160.77+0.53%
Dimensional - US Small Cap Value ETFDFSV- Market value
- 37.35M
- Weight
- 0.45%
- AUM
- 8.42B USD
- Expense ratio
- 0.30%
- Price / 1D
- $40.29+0.72%
Dimensional - US Targeted Value ETFDFAT- Market value
- 19.82M
- Weight
- 0.14%
- AUM
- 14.66B USD
- Expense ratio
- 0.28%
- Price / 1D
- $71.67+0.67%
State Street SPDR Portfolio Developed World ex-US ETFSPDW- Market value
- 16.86M
- Weight
- 0.04%
- AUM
- 41.92B USD
- Expense ratio
- 0.03%
- Price / 1D
- $52.02+0.79%
Thrivent Small-Mid Cap Equity ETFTSME- Market value
- 16.13M
- Weight
- 1.66%
- AUM
- 968.94M USD
- Expense ratio
- 0.65%
- Price / 1D
- $48.61+0.81%
Dimensional - US Core Equity 2 ETFDFAC- Market value
- 14.31M
- Weight
- 0.03%
- AUM
- 49.31B USD
- Expense ratio
- 0.17%
- Price / 1D
- $45.61+0.46%
Distillate U.S. Fundamental Stability & Value ETFDSTL- Market value
- 14.05M
- Weight
- 0.67%
- AUM
- 1.95B USD
- Expense ratio
- 0.39%
- Price / 1D
- $69.81+0.95%
Brown Advisory Sustainable Value ETFBASV- Market value
- 11.11M
- Weight
- 2.62%
- AUM
- 216.19M USD
- Expense ratio
- 0.71%
- Price / 1D
- $31.9487+0.44%
Vanguard Total World Stock ETFVT- Market value
- 10.25M
- Weight
- 0.01%
- AUM
- 97.9B USD
- Expense ratio
- 0.06%
- Price / 1D
- $160.77+0.53%
Continue in GoAI
Research ICLRresearch.disclaimer





